Empagliflozin prevents doxorubicin-induced myocardial dysfunction

Empagliflozin prevents doxorubicin-induced myocardial dysfunction

Abstract Background Empagliflozin showed efficacy in controlling glycaemia, leading to reductions in HbA1c levels, weight loss and blood pressure, compared to standard treatment. Moreover, the EMPA-REG OUTCOME trial demonstrated a 14% reduction of major adverse cardiovascular events (MACE), a 38% re...

Full description

Bibliographic Details
Main Authors: Jolanda Sabatino, Salvatore De Rosa, Laura Tammè, Claudio Iaconetti, Sabato Sorrentino, Alberto Polimeni, Chiara Mignogna, Andrea Amorosi, Carmen Spaccarotella, Masakazu Yasuda, Ciro Indolfi
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Cardiovascular Diabetology
Subjects:
Heart failure
Cardiotoxicity
Left ventricular function
Online Access:http://link.springer.com/article/10.1186/s12933-020-01040-5

Internet

http://link.springer.com/article/10.1186/s12933-020-01040-5

Similar Items